Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

From X

@convequity 3 clicks

Convequity on X

Inference repeatedly reads the same model weights, with far fewer writes than training. 1. In training, weights are constantly updated, so the memory sees heavy read and write traffic. 2. In inference, the dominant pattern is repeated reading of the same weights, and the key-value cache alongside them, with far fewer writes. That is the case for putting AI model weights on flash. Flash has traditionally been weaker than DRAM on write endurance and write speed. A read-heavy, write-light workload plays to its strengths and gets around exactly those weaknesses. Today AI chips sit beside HBM built from stacked DRAM, and it is the expensive part of the memory bill. High-Bandwidth Flash (HBF) is the product built on the read-heavy observation. It aims to deliver HBM-like read bandwidth at far higher capacity and lower cost by using NAND flash instead of DRAM. Two caveats. These are aims, not measured specifications. As of our early-August note, the first prototype from Sandisk ($SNDK), developed with SK Hynix, was expected later in the year. HBF is also more specialised than commodity NAND, where Chinese producers are expanding capacity aggressively.
@david_katunaric 1 click

Mikro Kap David on X

Q3 absolutely sucked, and my performance currently stands at 37.8% YTD versus 65.8% at the end of Q2, marking the worst drawdown from a high since I started sharing my buy/sell decisions on Substack. Apparently, the Market Gods decided this is what you get for calling your last portfolio update “Half-time Lead.” …I’m just glad I didn’t use a Buffett quote. That might’ve finished me off. While I barely felt the pre-2024 election volatility, the spring 2025 tariff scare, or the start of the Iran war in 2026, Q3 broke that pattern. $EVC, my largest position, fell more than 40% from its highs and made sure I felt this one. The portfolio’s relative resilience, something I’d come to appreciate, disappeared with it. Of course, I have plenty to say about Entravision, but I’ll save the fundamental developments for later in the article. Q3 was a season of portfolio pruning (wow, I never thought I’d use that phrase). I exited two winners, realized one loss, added to a large position, saw a rare billion-dollar-plus company find its way into my portfolio, and ended the quarter with 6% in cash versus 0% at the end of Q2. I ended Q3 with 11 holdings, with the top three accounting for 53% of capital and the top five for 70%. Portfolio beta also came down from 0.95 at the end of Q2 to 0.80 at quarter end. That is still elevated relative to the portfolio’s historical level, largely because my biggest position carries a beta of 1.68, while every other holding sits below 1. I’ll save the longer performance review for year end, when we can hopefully put what I still consider a satisfactory 2026 into proper perspective. For now, I think it’s better to focus on what actually matters for a concentrated stock picker like me: what has changed fundamentally, how those developments affect the risk/reward, and where my conviction stands today. As usual, at the link below I went through the portfolio from the smallest position to the largest.

Investor Letters

All letters

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

MYRG $4B
Monte Independent Investment Research 5 clicks

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 28 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $108M
Triple S Special Situations Investing 4 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $108M
Value Investors Club

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 56 of 248

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.